Evidence map›Paper›PMID 34374417›Full record

ArticleJournal of cell science2021

Tumour cell CD99 regulates transendothelial migration via CDC42 and actin remodelling.

Aarren J Mannion, Adam F Odell, Alison Taylor, Pamela F Jones, Graham P Cook

Open access · hybridAbstract read
In one paragraph

Article in Journal of cell science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Aarren J MannionLeeds Institute for Medical Research, University of Leeds School of Medicine, St. James's University Hospital, Leeds LS8 2BH, UK.ORCID 0000-0002-1837-986X
Adam F OdellLeeds Institute for Medical Research, University of Leeds School of Medicine, St. James's University Hospital, Leeds LS8 2BH, UK.ORCID 0000-0002-6855-7214
Alison TaylorLeeds Institute for Medical Research, University of Leeds School of Medicine, St. James's University Hospital, Leeds LS8 2BH, UK.ORCID 0000-0003-2295-2611
Pamela F JonesLeeds Institute for Medical Research, University of Leeds School of Medicine, St. James's University Hospital, Leeds LS8 2BH, UK.ORCID 0000-0001-8144-4436
Graham P CookLeeds Institute for Medical Research, University of Leeds School of Medicine, St. James's University Hospital, Leeds LS8 2BH, UK.ORCID 0000-0003-0223-3652
University of Leeds · GB

Funding

Cancer Research UK A20105Wellcome TrustWellcome Trust WELLCOME TRUST/UNIVERSITY LEEDS STRATEGIC SUPPORT FUND
6 · The paper itself

Abstract

Metastasis requires tumour cells to cross endothelial cell (EC) barriers using pathways similar to those used by leucocytes during inflammation. Cell surface CD99 is expressed by healthy leucocytes and ECs, and participates in inflammatory transendothelial migration (TEM). Tumour cells also express CD99, and we have analysed its role in tumour progression and cancer cell TEM. Tumour cell CD99 was required for adhesion to ECs but inhibited invasion of the endothelial barrier and migratory activity. Furthermore, CD99 depletion in tumour cells caused redistribution of the actin cytoskeleton and increased activity of the Rho GTPase CDC42, known for its role in actin remodelling and cell migration. In a xenograft model of breast cancer, tumour cell CD99 expression inhibited metastatic progression, and patient samples showed reduced expression of the CD99 gene in brain metastases compared to matched primary breast tumours. We conclude that CD99 negatively regulates CDC42 and cell migration. However, CD99 has both pro- and anti-tumour activity, and our data suggest that this results in part from its functional linkage to CDC42 and the diverse signalling pathways downstream of this Rho GTPase. This article has an associated First Person interview with the first author of the paper.

Indexed as

ActinsNeoplasms12E7 Antigencdc42 GTP-Binding ProteinCell MovementHumansrho GTP-Binding ProteinsTransendothelial and Transepithelial Migration12E7 AntigenActinsCD99 protein, humancdc42 GTP-Binding Proteinrho GTP-Binding ProteinsActin cytoskeletonBreast cancerCD99CDC42MetastasisTransendothelial migration

Identifiers

PMID34374417
PMCPMC8403985
OpenAlexW3185807290

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.